Scott D. Ramsey

Appointments and Affiliations

Fred Hutchinson Cancer Research Center
Cancer Prevention Research Program
Public Health Sciences
Full Member, Appointed: 2005
Seattle Cancer Care Alliance
Cancer Prevention Clinic
Director, Appointed: 2006
University of Washington
School of Medicine
Medicine
Professor, Appointed: 2006
Professional Headshot of Scott D. Ramsey

Mailing Address

1100 Fairview Avenue North
M3-B232
Seattle, Washington 98109-1024
United States

Contact

Phone: (206) 667-7846
Fax: (206) 667-5977
sramsey@fhcrc.org

Degrees

Ph.D., University of Pennsylvania, 1994.
M.D., University of Iowa, 1990.
B.S., University of Iowa, 1983.

Research Interests

Cost Effectiveness
Health Related Quality of Life



Additional Experience

Internship and Residency in Internal Medicine

Future Research

A Retrospective Evaluation of Patterns of Care for American Indian and Alaska Native Men with Elevated Prostate Specific Antigen

Linking Cancer Registries with Medicaid to Measure Cancer Treatment and Outcomes

Promoting Cancer Screening Among American Indians through Art and Storytelling

Physician and Navigator Discussion Guides in Prostate Cancer: A Controlled Trial

A Study of Cancer Diagnosis as a Risk Factor for Personal Bankruptcy

Blood Product Use among Persons with Myelodysplastic Syndrome

Memberships

American College of Physicians
American Society of Clinical Oncology
Cancer Intervention and Surveillance Network
International Health Economics Association
International Society for Pharmacoeconomic and Outcomes Research
Society for Medical Decision Making

Honors and Awards

1997-1998, Howard Temin Career Development Award, National Cancer Institute
1996-1997, Robert Wood Johnson Faculty Support Award, University of Washington
1995-1996, Robert H. Williams Award, American Federation for Clinical Research
1994-1995, Cecile Lehman Mayer Research Award recipient, American College of Chest Physicians
1991-1992, John and Oral Sebelin Award - Outstanding Student in Internal Medicine, College of Medicine, University of Iowa
1989-1990, University Research Foundation support grant, Wharton School, University of Pennsylvania
1987-1988, Dean's Scholarship, Wharton School, University of Pennsylvania
1986-1987, Kellogg Washington Health Policy Fellowship, Wharton School, University of Pennsylvania
1983-1984, University of Iowa Certificate of Achievement, University of Iowa
1982-1983, Chester A. Phillips Scholarship, College of Medicine, University of Iowa
1982-1983, Mortar Board, University of Iowa, University of Iowa
1982-1983, Omicron Delta Kappa, Omicron Delta Kappa--national leadership society,, University of Iowa
1982-1983, BeBeta Gamma Sigma, Beta Gamma Sigma--honorary fraternity in business, University of Iowa
1980-1981, University of Iowa Merit Award, College of Medicine, University of Iowa

Previous Positions

2001-2006, Associate Professor, University of Washington, School of Medicine, Medicine, General Internal Medicine
2000-2005, Associate Member, Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences
1997-2000, Assistant Professor, University of Washington, School of Medicine, Medicine, General Internal Medicine
1997-2000, Assistant Professor, University of Washington, School of Public Health and Community Medicine, Health Services
1997-2000, Joint Assistant Member, Fred Hutchinson Cancer Research Center, Public Health Sciences Division
1995-1998, Staff Physician, VA Puget Sound Health Care System, Seattle Divison
1995-1997, Acting Assistant Professor, University of Washington, Health Sciences
1995-2000, Director, University of Washington, Center for Cost and Outcomes Research, Clinical Economics
1995-1997, Acting Assistant Professor, University of Washington, School of Medicine, Medicine, General Internal Medicine
1994-1995, Chief Medical Resident, University of Washington, Medical Center, Medicine
1994-1995, Acting Instructor, University of Washington, School of Medicine, Medicine
1993-1994, Fellow, University of Washington, School of Medicine, Medicine, General Internal Medicine
1990-1993, University of Washington, Internal Medicine

Funding

  • NOVA Research Company: A Cost Effectiveness Evaluation (CEA) of the Program Evaluation of Patient Navigator Research Program, $22,053, 2007 to 2012.
  • Amgen: A Retrospective Evaluation of Completion of Planned Radiation Therapy and Survival Among Medicare Enrollees with Head and Neck, $166,426, 2007 to 2008.
  • Amgen: Developing a Research Protocol to Identify Predictors of Use and Outcomes for Lung, Colorectal and Breast Cancer Patients Receiving Biological Agents and Traditional Chemotherapy Using a Linked Cancer Registry and Claims Database, $47,615, 2007 to 2008.
  • NIH/NCI: Reassessing the Quality of Life Burden of Prostate Cancer Survivorship, $100,000, 2007 to 2009.
  • NIH/NCI: A Multi-State Study of Cancer Treatment and Outcomes Among American Indians, $1,390,366, 2007 to 2012.
  • NIH/NCI: Additional Evaluations of Treatment Choice and Quality of Life for Men with Localized Prostate Cancer, $19,931, 2007 to 2008.
  • Genentech: Development and Validation of a Claims-Based Algorithm to Identify Incident Cases of Non-Small Cell Lung Cancer, $126,604, 2006 to 2008.
  • Bristol-Meyers Squibb: Patterns of Health Care Utilization and Medical Costs for Older Persons with Advanced Non-Small Cell Lung Cancer, $59,447, 2005 to 2007.
  • NIH/NCI: Cervical Cancer Control in Vietnamese Women, $348,603, 2005 to 2009.
  • NIH/NCI: Regional Native American Community Networks Program, Research Project for, $90,000, 2005 to 2010.
  • Centers for Disease Control and Prevention: Determinants of Patient Dropout from Cancer Treatment and Follow-Up, $85,000, 2005 to 2007.
  • Amgen: A Retrospective Evaluation of Colony Stimulating Factor (CSF) Use in Patients with Breast and Lung Cancer, $310,000, 2005 to 2009.
  • Genentech: Patterns of Second Line Chemotherapy Use and Direct Medical Costs for Persons with Non-Small Cell Cancer, $108,000, 2005 to 2008.
  • NIH/NHGRI: Genomic Health Care and the Medically Underserved, $787,083, 2004 to 2008.
  • National Institutes of Health (NIH): A Genetic Screening Policy Model for Colorectal Cancer, $205,000, 2004 to 2009.
  • NIH/NCI: Linking the Washington State Cancer Registry with Medicaid and NPAIHB Records, $66,212, 2004 to 2007.
  • Centers for Disease Control and Prevention: Localized Prostate Cancer: Decision Making and Outcomes, $86,759, 2004 to 2009.
  • NIH/NCI: SEER Special Studies: Special Study #04-5 "Treatment Choice and Quality of Life for Men with Localized Prostate Cancer", $206,700, 2004 to 2008.
  • Britsol-Meters Squibb: Treatment Patterns and Direct Medical Costs for Persons Age 65 and Higher with Advanced Bladder Cancer, $57,076, 2004 to 2007.
  • Fred Hutchinson Cancer Research Center (Center Funds): A Roadmap for Early Detection Research, $50,000, 2004 to 2006.
  • NIH: A Survey of Physician and Health Insurer Attitudes towards Risk-Stratified Colorectal Cancer Screening, $140,194, 2004 to 2009.
  • NIH/NCI: CanCORS: Lung/Colon Cancer Outcomes: Cancer Researhc Network (Co-PI for special project), $72,286, 2001 to 2007.
  • NIH/NCI: Biobehavioral Cancer Prevention & Control Training Program, $240,579, 2001 to 2011.

Recent Publications

2013
Simonds, NI, Khoury MJ, Schully SD, Armstrong K, Cohn WF, Fenstermacher DA, Ginsburg GS, Goddard KAB, Knaus WA, Lyman GH et al..  2013.  Comparative Effectiveness Research in Cancer Genomics and Precision Medicine: Current Landscape and Future Prospects.. Journal of the National Cancer Institute. Abstract
Ramsey, SD, Sullivan SD, Reed SD, Tina Shih Y-C, Schaecher K, Dhanda R, Patt D, Pendergrass K, Walker M, Malin J et al..  2013.  Oncology Comparative Effectiveness Research: A Multistakeholder Perspective on Principles for Conduct and Reporting.. The oncologist. Abstract
Carlson, JJ, Thariani R, Roth J, Gralow J, Henry LN, Esmail L, Deverka P, Ramsey SD, Baker L, Veenstra DL.  2013.  Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics.. Medical decision making : an international journal of the Society for Medical Decision Making. 33(4):463-71. Abstract
Goulart, BHL, Reyes CM, Fedorenko CR, Mummy DG, Satram-Hoang S, Koepl LM, Blough DK, Ramsey SD.  2013.  Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer.. Journal of oncology practice / American Society of Clinical Oncology. 9(1):42-50. Abstract
Flowers, CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KVI et al..  2013.  Antimicrobial prophylaxis and outpatient management of Fever and neutropenia in adults treated for malignancy: american society of clinical oncology clinical practice guideline.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(6):794-810. Abstract
Goulart, BHL, Ramsey SD.  2013.  lung cancer screening with low-dose computed tomography.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(4):366-7.
2012
Ramsey, SD, Barlow WE, Gonzalez-Angulo AM, Tunis S, Baker L, Crowley J, Deverka P, Veenstra D, Hortobagyi GN.  2012.  Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.. Contemporary clinical trials. 34(1):1-9. Abstract
Esmail, LC, Roth J, Rangarao S, Carlson JJ, Thariani R, Ramsey SD, Veenstra DL, Deverka P.  2012.  Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research.. Genetics in medicine : official journal of the American College of Medical Genetics. Abstract
Wong, WB, Ramsey SD, Barlow WE, Garrison LP, Veenstra DL.  2012.  The value of comparative effectiveness research: Projected return on investment of the RxPONDER trial (SWOG S1007).. Contemporary clinical trials. 33(6):1117-23. Abstract
Shankaran, V, Jolly S, Blough D, Ramsey SD.  2012.  Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(14):1608-14. Abstract
Ramsey, SD, Zeliadt SB, Blough DK, Fedorenko CR, Fairweather ME, McDermott CL, Penson DF, Van Den Eeden SK, Hamilton AS, Arora NK.  2012.  Complementary and alternative medicine use, patient-reported outcomes, and treatment satisfaction among men with localized prostate cancer.. Urology. 79(5):1034-41. Abstract
Ramsey, SD, McCune JS, Blough DK, McDermott CL, Beck SJ, López JA, Joachim Deeg H.  2012.  Patterns of blood product use among patients with myelodysplastic syndrome.. Vox sanguinis. 102(4):331-337. Abstract
Ramsey, SD, Holmes RS, McDermott CL, Blough DK, Petrin KL, Poole EM, Ulrich CM.  2012.  A Comparison of Approaches for Association Studies of Polymorphisms and Colorectal Cancer Risk.. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. Abstract
Erickson, SC, Le L, Zakharyan A, Stockl KM, Harada ASM, Borson S, Ramsey SD, Curtis B.  2012.  New-Onset Treatment-Dependent Diabetes Mellitus and Hyperlipidemia Associated with Atypical Antipsychotic Use in Older Adults without Schizophrenia or Bipolar Disorder.. Journal of the American Geriatrics Society. 60(3):474-479. Abstract
Deverka, PA, Lavallee DC, Desai PJ, Armstrong J, Gorman M, Hole-Curry L, O'Leary J, Ruffner B, Watkins J, Veenstra DL et al..  2012.  Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process.. Journal of comparative effectiveness research. 1(4):359-370. Abstract
Li, C, Zeliadt SB, Hall IJ, Smith JL, Ekwueme DU, Moinpour CM, Penson DF, Thompson IM, Keane TE, Ramsey SD.  2012.  Willingness to Pay for Prostate Cancer Treatment among Patients and Their Family Members at 1 Year After Diagnosis.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 15(5):716-23. Abstract
McDermott, CL, Blough DK, Fedorenko CR, Arora NK, Zeliadt SB, Fairweather ME, Oakley-Girvan I, Van Den Eeden SK, Ramsey SD.  2012.  Complementary and alternative medicine use among newly diagnosed prostate cancer patients.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 20(1):65-73. Abstract
Scoggins, JF, Fedorenko CR, Donahue SMA, Buchwald D, Blough DK, Ramsey SD.  2012.  Is distance to provider a barrier to care for medicaid patients with breast, colorectal, or lung cancer? The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association. 28(1):54-62. Abstract
Cheng, MM, Ramsey SD, Devine EB, Garrison LP, Bresnahan BW, Veenstra DL.  2012.  Systematic review of comparative effectiveness data for oncology orphan drugs.. The American journal of managed care. 18(1):47-62. Abstract
Goulart, BHL, Bensink ME, Mummy DG, Ramsey SD.  2012.  Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(2):267-75. Abstract
Carlson, JJ, Ramsey SD.  2012.  Proof or principle? On economic modeling to guide genomic testing in metastatic colorectal cancer. Journal of the National Cancer Institute. 104(23):1779-80.
Curtis, RJ, Engelberg RA, Bensink ME, Ramsey SD.  2012.  End-of-life Care in the ICU: Can We Simultaneously Increase Quality and Reduce Costs? American journal of respiratory and critical care medicine. Abstract
Deverka, PA, Schully SD, Ishibe N, Carlson JJ, Freedman A, Goddard KAB, Khoury MJ, Ramsey SD.  2012.  Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies.. Genetics in medicine : official journal of the American College of Medical Genetics. Abstract
Ramsey, SD, McDermott CL, Clarke L, Blough DK.  2012.  Health insurer policies toward risk-stratified colorectal cancer screening: a survey of health plan medical directors.. Journal of insurance medicine (New York, N.Y.). 43(2):92-101. Abstract
2011
Goulart, B, Ramsey SD.  2011.  A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 14(6):836-45. Abstract